Concentra picks up a new Cargo
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
Conjugates dominate human trial entries
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Safety remains the key metric for Cogent
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
Regeneron enters the T-cell engager arena
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
M&A analysis: signs of life emerge
Some big deals in the second quarter have raised hopes that takeouts are back.
Dizal's US first; now what?
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
BeOne also needs B7-H4 biomarkers
The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.
The month ahead: July’s upcoming events
Regeneron is facing two FDA decisions for its T-cell engagers.
BeOne tries to repeat the inhibitor-degrader double
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
